Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Reuters

09/09

Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Veracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery $(GRID)$. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566695690"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566695690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566695690?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566695690","market":"fut","top_or_hot":-1,"title":"Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery <a href=\"https://laohu8.com/S/GRID\">$(GRID)$</a>. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-09 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VCYT\">Veracyte Inc</a>., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery <a href=\"https://laohu8.com/S/GRID\">$(GRID)$</a>. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL57DJP8:1","article_id":"2566695690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566695690","pubTimestamp":1757422912,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery . This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc"},"translate_title":"Veracyte将在2025年美国甲状腺协会年会上展示10多项以Afirma为重点的研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":0.9},"content_text":"Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting\n    \n\nVeracyte Inc., a leading cancer diagnostics company, has announced the presentation of 12 Afirma-related abstracts at the upcoming 2025 American Thyroid Association Annual Meeting. Scheduled from September 10-14 at the Westin Kierland in Scottsdale, Arizona, these studies highlight Veracyte's extensive work in thyroid cancer research, utilizing their Afirma Genomic Resource for Intelligent Discovery $(GRID)$. This resource is noted as the largest molecular database for thyroid nodules. The abstracts, which will be presented in the future at the meeting, cover a range of topics including potential prognostic and therapeutic markers in thyroid tumors, preoperative thyroid nodule mRNA expression signatures, and molecular profiling of patients with indeterminate thyroid nodules. The studies aim to advance scientific understanding and inform innovations in patient care within the field of thyroid cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250909813969) on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}